

## Freedom of Information (Scotland) Act 2002

<b>Date received</b>	23/08/2022	<b>Subject</b>	Drug Treatment		
<b>Passed to</b>	Pharmacy	<b>Date passed</b>	24/08/2022	<b>Respond by</b>	13/09/2022
<b>Category</b>	Research	<b>FOI number</b>	2022-340		

### Question/s to be answered

1. Does your trust treat myelofibrosis? If not, which other trust do you refer these patients to?

All patients with this condition would be diagnosed and treated by NHS Grampian on behalf of NHS Shetland

2. a) Please provide the total number of patients treated in the last 6 months (or the latest 6 months data you have available) for myelofibrosis (ICD10 code D47.4).

None

- b) How many of these patients were above age 65?

N/A

3. How many myelofibrosis patients were treated in the past 6 months with Ruxolitinib?

See answer to Q1

4. a) How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

See answer to Q1

- b) Of these patients, how many were treated in the past 6 months (or the latest 6 months data you have available) with:

- Hydroxyurea
- Fedratinib
- Received No Treatment

N/A

5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?

No